The California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) announced that it intends to list bevacizumab as known to the state to cause reproductive toxicity (developmental and female endpoints) under the Safe Drinking Water and Toxic Enforcement Act of 1986, more commonly known as Proposition 65. OEHHA notes that this action is being proposed under the “Formally Required to Be Labeled or Identified” listing mechanism. which is most often used to list certain drugs approved by the U.S Food and Drug Administration that cover or contain chemical compounds under Proposition 65. Listings under the Formally Required to be labeled or Identified listing mechanism are rarely contested in any meaningful way.
For example, the proposed listing of Bevacizumab is a cancer treatment drug known by its brand name, Avastin. It is a treatment for many different types of cancers, such as colon cancer, non-small lung cancer and also in the treatment of ovarian cancer. It is also used in chemotherapy.
Female reproductive toxicity
Latest posts by Jack Schatz (see all)
- California Attorney General Obtains $1.6 Million Default Judgment Against LA Based Jewelry Seller - May 5, 2018
- EPA Administrator Scott Pruitt Resigns - July 6, 2018
- Democrats Demand Hearing on TSCA Implementation - September 6, 2018